MedTrace Logo

VIA Disc Nucleus Pulposus Older Patients Pilot

NCT05412277 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2024-04-29

No results posted yet for this study

Summary

VIA Disc NP is a non-surgical intervention intended to supplement the nucleus pulposus tissue in degenerated intervertebral discs.

Conditions

  • Degenerative Disc Disease
  • Low Back Pain
  • Disc Degeneration

Interventions

OTHER

VIA Disc Nucleus Pulposus Allograft

A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 to 3 levels, L1-S1.

Sponsors & Collaborators

  • VIVEX Biologics, Inc.

    lead INDUSTRY

Principal Investigators

  • Nomen Azeem, MD · Florida Spine & Pain Specialists

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-17
Primary Completion
2024-08-30
Completion
2024-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05412277 on ClinicalTrials.gov